HRP20230931T1 - Kristalični oblici n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil)fenil)kinolin-8-sulfonamida - Google Patents
Kristalični oblici n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil)fenil)kinolin-8-sulfonamida Download PDFInfo
- Publication number
- HRP20230931T1 HRP20230931T1 HRP20230931TT HRP20230931T HRP20230931T1 HR P20230931 T1 HRP20230931 T1 HR P20230931T1 HR P20230931T T HRP20230931T T HR P20230931TT HR P20230931 T HRP20230931 T HR P20230931T HR P20230931 T1 HRP20230931 T1 HR P20230931T1
- Authority
- HR
- Croatia
- Prior art keywords
- crystalline form
- preparation
- tablet
- individual
- pharmaceutical preparation
- Prior art date
Links
- XAYGBKHKBBXDAK-UHFFFAOYSA-N n-[4-[4-(cyclopropylmethyl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide Chemical compound C=1C=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=CC=1C(=O)N(CC1)CCN1CC1CC1 XAYGBKHKBBXDAK-UHFFFAOYSA-N 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims 5
- 208000002903 Thalassemia Diseases 0.000 claims 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 108700014121 Pyruvate Kinase Deficiency of Red Cells Proteins 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 239000007916 tablet composition Substances 0.000 claims 2
- 206010014490 Elliptocytosis hereditary Diseases 0.000 claims 1
- 208000001825 Hereditary elliptocytosis Diseases 0.000 claims 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 208000004622 abetalipoproteinemia Diseases 0.000 claims 1
- 201000006288 alpha thalassemia Diseases 0.000 claims 1
- 208000005980 beta thalassemia Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 208000009601 hereditary spherocytosis Diseases 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 229940071138 stearyl fumarate Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (13)
1. Kristalični oblik od spoja koji je predstavljen sljedećom formulom:
[image]
gdje spoj je seskvihidrat; i pritom kristalični oblik je kristalični Oblik A, naznačen time, da ima maksimume rendgenske difrakcije na prahu pod 2Θ kutovima (± 0,2°) 9,9°, 15,8°, i 22,6°.
2. Kristalični oblik prema patentnom zahtjevu 1, pri čemu kristalični oblik je kristalični Oblik A, naznačen time, da ima maksimume rendgenske difrakcije na prahu pod 2Θ kutovima (± 0,2°) 9,9°, 15,8°, i 22,6°, i najmanje jedan, najmanje dva, ili najmanje tri dodatna maksimuma rendgenske difrakcije na prahu pod 2Θ kutovima (± 0,2°) odabrana od 15,0°, 17,1°, 21,3°, i 21,9°.
3. Kristalični oblik prema patentnom zahtjevu 2, pri čemu kristalični oblik je kristalični Oblik A, naznačen time, da ima maksimume rendgenske difrakcije na prahu pod 2Θ kutovima (± 0,2°) 9,9°, 11,4°, 15,0°, 15,3°, 15,8°, 17,1°, 17,7°, 21,3°, 21,9°, 22,6°, i 23,5°.
4. Kristalični oblik prema patentnom zahtjevu 3, pri čemu kristalični oblik je kristalični Oblik A, naznačen time, da ima maksimume rendgenske difrakcije na prahu pod 2Θ kutovima (± 0,2°) 4,9°, 9,9°, 11,0°, 11,4°, 11,7°, 12,3°, 12,8°, 13,6°, 13,9°, 14,2°, 15,0°, 15,3°, 15,8°, 17,1°, 17,4°, 17,7°, 18,8°, 19,1°, 19,8°, 21,3°, 21,9°, 22,6°, 23,0°, 23,2°, 23,5°, 23,8°, 24,1°, 24,5°, 25,3°, 25,6°, 26,1°, 27,1°, 28,1°, i 29,8°.
5. Farmaceutski pripravak, naznačen time, da sadrži kristalični oblik prema bilo kojem od patentnih zahtjeva 1 do 4, i farmaceutski prihvatljiv nosač.
6. Pripravak u tableti, naznačen time, da sadrži kristalični oblik prema bilo kojem od patentnih zahtjeva 1 do 4, i farmaceutski prihvatljiv nosač.
7. Farmaceutski pripravak prema patentnom zahtjevu 5 ili pripravak u tableti prema patentnom zahtjevu 6, naznačen time, da se nosač bira od jednog ili više od mikrokristalične celuloze, manitola, kroskarmeloze natrij, i natrijevog stearil fumarata.
8. Pripravak u tableti prema patentnom zahtjevu 6 ili zahtjevu 7, naznačen time, da pripravak sadrži 5,7 do 5,9 mg, 23,4 do 23,6 mg, ili 58,7 do 58,9 mg kristaličnog Oblika A; 62% masa/masa (± 2%) mikrokristalične celuloze; 23% masa/masa (± 2%) manitola; 3% masa/masa (± 2%) kroskarmeloze natrij; i 2% masa/masa (± 2%) stearil fumarata.
9. Kristalični oblik prema bilo kojem od patentnih zahtjeva 1 do 4, ili farmaceutski pripravak ili pripravak u tableti prema bilo kojem od patentnih zahtjeva 5 do 8, naznačen time, da je za uporabu u postupku liječenja nedostatka piruvat kinaze (PKD) kod pojedinca kojemu je to potrebno, pri čemu postupak obuhvaća davanje pojedincu učinkovite količine navedenog kristaličnog Oblika A, ili navedenog farmaceutskog pripravka ili pripravka u tableti.
10. Kristalični oblik prema bilo kojem od patentnih zahtjeva 1 do 4, ili farmaceutski pripravak ili pripravak u tableti prema bilo kojem od patentnih zahtjeva 5 do 8, naznačen time, da je za uporabu u postupku liječenja bolesti srpastih stanica (SCD) kod pojedinca kojemu je to potrebno, pri čemu postupak obuhvaća davanje pojedincu učinkovite količine navedenog kristaličnog Oblika A, ili navedenog farmaceutskog pripravka ili pripravka u tableti.
11. Kristalični oblik prema bilo kojem od patentnih zahtjeva 1 do 4, ili farmaceutski pripravak ili pripravak u tableti prema bilo kojem od patentnih zahtjeva 5 do 8, naznačen time, da je za uporabu u postupku liječenja talasemije, kao što su alfa-talasemija, beta-talasemija, talasemija neovisna o transfuziji, i talasemija ovisna o transfuziji, kod pojedinca kojemu je to potrebno, pri čemu postupak obuhvaća davanje pojedincu učinkovite količine navedenog kristaličnog Oblika A, ili navedenog farmaceutskog pripravka ili pripravka u tableti.
12. Kristalični oblik prema bilo kojem od patentnih zahtjeva 1 do 4, ili farmaceutski pripravak ili pripravak u tableti prema bilo kojem od patentnih zahtjeva 5 do 8, naznačen time, da je za uporabu u postupku liječenja hemolitičke anemije kod pojedinca kojemu je to potrebno, pri čemu postupak obuhvaća davanje pojedincu učinkovite količine navedenog kristaličnog Oblika A, ili navedenog farmaceutskog pripravka ili pripravka u tableti.
13. Kristalični oblik prema bilo kojem od patentnih zahtjeva 1 do 4, ili farmaceutski pripravak ili pripravak u tableti prema bilo kojem od patentnih zahtjeva 5 do 8, naznačen time, da je za uporabu u postupku liječenja bolesti koja se bira od nasljedne sferocitoze, nasljedne eliptocitoze, abetalipoproteinemije, sindroma Bassen-Kornzweig, i paroksizmalne noćne hemoglobinurije, kod pojedinca kojemu je to potrebno, pri čemu postupak obuhvaća davanje pojedincu učinkovite količine navedenog kristaličnog Oblika A, ili navedenog farmaceutskog pripravka ili pripravka u tableti.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589822P | 2017-11-22 | 2017-11-22 | |
| US201862691709P | 2018-06-29 | 2018-06-29 | |
| PCT/US2018/062197 WO2019104134A1 (en) | 2017-11-22 | 2018-11-21 | Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
| EP18821779.8A EP3713919B1 (en) | 2017-11-22 | 2018-11-21 | Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230931T1 true HRP20230931T1 (hr) | 2023-11-24 |
Family
ID=64734113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230931TT HRP20230931T1 (hr) | 2017-11-22 | 2018-11-21 | Kristalični oblici n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil)fenil)kinolin-8-sulfonamida |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11254652B2 (hr) |
| EP (2) | EP4285904A3 (hr) |
| JP (2) | JP7275130B2 (hr) |
| KR (1) | KR20200090787A (hr) |
| CN (2) | CN111372920B (hr) |
| AU (2) | AU2018373122B2 (hr) |
| BR (1) | BR112020010185A2 (hr) |
| CA (1) | CA3081945A1 (hr) |
| DK (1) | DK3713919T3 (hr) |
| ES (1) | ES2959764T3 (hr) |
| FI (1) | FI3713919T3 (hr) |
| HR (1) | HRP20230931T1 (hr) |
| HU (1) | HUE063264T2 (hr) |
| IL (2) | IL305343A (hr) |
| LT (1) | LT3713919T (hr) |
| MD (1) | MD3713919T2 (hr) |
| MX (2) | MX2020005348A (hr) |
| PH (1) | PH12020550644A1 (hr) |
| PL (1) | PL3713919T3 (hr) |
| PT (1) | PT3713919T (hr) |
| RS (1) | RS64592B1 (hr) |
| SG (1) | SG11202004587XA (hr) |
| SI (1) | SI3713919T1 (hr) |
| TW (2) | TWI808108B (hr) |
| UA (1) | UA127502C2 (hr) |
| WO (1) | WO2019104134A1 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG177434A1 (en) * | 2009-06-29 | 2012-02-28 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
| MD3448859T2 (ro) | 2017-03-20 | 2020-03-31 | Forma Therapeutics Inc | Compoziții de pirolopirol în calitate de activatori ai piruvatkinazei (PKR) |
| BR112021005188A2 (pt) | 2018-09-19 | 2021-06-08 | Forma Therapeutics, Inc. | tratamento de anemia falciforme com um composto de ativação de piruvato cinase r |
| JP7450610B2 (ja) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | ピルビン酸キナーゼｒの活性化 |
| MX2021014228A (es) * | 2019-05-22 | 2022-02-21 | Agios Pharmaceuticals Inc | Formas cristalinas de sal de n-(4-(4 (ciclopropilmetil)piperazin 1- carbonil)fenil)quinolin-8-sulfonamida. |
| US11878049B1 (en) * | 2019-06-14 | 2024-01-23 | Agios Pharmaceuticals, Inc. | Mitapivat therapy and modulators of cytochrome P450 |
| WO2021154987A1 (en) | 2020-01-28 | 2021-08-05 | Teva Pharmaceuticals International Gmbh | Solid state forms of mitapivat and process for preparation thereof |
| AU2021347349A1 (en) * | 2020-09-25 | 2023-06-08 | Agios Pharmaceuticals, Inc. | Pharmaceutical formulation |
| WO2022231627A1 (en) | 2021-04-30 | 2022-11-03 | Agios Pharmaceuticals, Inc. | Methods for titrating mitapivat for use in treating thalassemia |
| WO2023154036A1 (en) | 2022-02-08 | 2023-08-17 | Agios Pharmaceuticals, Inc. | Methods for titrating mitapivat |
| KR20240004620A (ko) | 2021-04-30 | 2024-01-11 | 아지오스 파마슈티컬스 아이엔씨. | 미타피바트를 적정하는 방법 |
| EP4147700A1 (en) * | 2021-09-08 | 2023-03-15 | LQT Therapeutics Inc. | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease |
| CA3236880A1 (en) | 2021-11-16 | 2023-05-25 | Agios Pharmaceuticals, Inc. | Compounds for treating mds-associated anemias and other conditions |
| WO2024084501A1 (en) | 2022-10-17 | 2024-04-25 | Mylan Laboratories Limited | Crystalline polymorphs of mitapivat and mitapivat hemisulfate |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN191496B (hr) * | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
| GB2383042A (en) * | 2001-10-18 | 2003-06-18 | Cipla Ltd | Amorphous alendronate sodium |
| SG177434A1 (en) | 2009-06-29 | 2012-02-28 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
| CN111728971A (zh) * | 2012-09-18 | 2020-10-02 | 奥斯拜客斯制药有限公司 | D6-四苯喹嗪固体口服剂型、化合物、及其药物组合物、制备及治疗方法 |
| WO2016201227A1 (en) * | 2015-06-11 | 2016-12-15 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
-
2018
- 2018-11-21 IL IL305343A patent/IL305343A/en unknown
- 2018-11-21 MX MX2020005348A patent/MX2020005348A/es unknown
- 2018-11-21 CA CA3081945A patent/CA3081945A1/en active Pending
- 2018-11-21 PL PL18821779.8T patent/PL3713919T3/pl unknown
- 2018-11-21 HU HUE18821779A patent/HUE063264T2/hu unknown
- 2018-11-21 FI FIEP18821779.8T patent/FI3713919T3/fi active
- 2018-11-21 KR KR1020207015018A patent/KR20200090787A/ko active IP Right Grant
- 2018-11-21 ES ES18821779T patent/ES2959764T3/es active Active
- 2018-11-21 HR HRP20230931TT patent/HRP20230931T1/hr unknown
- 2018-11-21 RS RS20230793A patent/RS64592B1/sr unknown
- 2018-11-21 AU AU2018373122A patent/AU2018373122B2/en active Active
- 2018-11-21 EP EP23186155.0A patent/EP4285904A3/en active Pending
- 2018-11-21 CN CN201880075099.8A patent/CN111372920B/zh active Active
- 2018-11-21 UA UAA202003680A patent/UA127502C2/uk unknown
- 2018-11-21 JP JP2020528129A patent/JP7275130B2/ja active Active
- 2018-11-21 US US16/765,456 patent/US11254652B2/en active Active
- 2018-11-21 SI SI201830984T patent/SI3713919T1/sl unknown
- 2018-11-21 EP EP18821779.8A patent/EP3713919B1/en active Active
- 2018-11-21 MD MDE20200988T patent/MD3713919T2/ro unknown
- 2018-11-21 TW TW107141542A patent/TWI808108B/zh active
- 2018-11-21 WO PCT/US2018/062197 patent/WO2019104134A1/en active Application Filing
- 2018-11-21 BR BR112020010185-0A patent/BR112020010185A2/pt unknown
- 2018-11-21 TW TW112118933A patent/TW202334115A/zh unknown
- 2018-11-21 PT PT188217798T patent/PT3713919T/pt unknown
- 2018-11-21 LT LTEPPCT/US2018/062197T patent/LT3713919T/lt unknown
- 2018-11-21 IL IL274488A patent/IL274488B2/en unknown
- 2018-11-21 DK DK18821779.8T patent/DK3713919T3/da active
- 2018-11-21 SG SG11202004587XA patent/SG11202004587XA/en unknown
- 2018-11-21 CN CN202311301795.5A patent/CN117551030A/zh active Pending
-
2020
- 2020-05-15 PH PH12020550644A patent/PH12020550644A1/en unknown
- 2020-07-13 MX MX2022009998A patent/MX2022009998A/es unknown
-
2022
- 2022-01-14 US US17/575,898 patent/US20220220093A1/en active Pending
-
2023
- 2023-05-02 JP JP2023076364A patent/JP2023093762A/ja active Pending
-
2024
- 2024-02-06 AU AU2024200724A patent/AU2024200724A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230931T1 (hr) | Kristalični oblici n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil)fenil)kinolin-8-sulfonamida | |
| HRP20192065T1 (hr) | Čvrsti oblici doziranja palbocikliba | |
| HRP20210343T1 (hr) | Soli ili ko-kristali 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola | |
| JP2021504338A5 (hr) | ||
| HRP20210487T1 (hr) | Farmaceutski sastavi koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo | |
| HRP20170677T1 (hr) | Farmaceutski sastav za kontrolirano otpuštanje koji sadrži ester fumarne kiseline | |
| RU2008113439A (ru) | Композиции с замедленным высвобождением лекарственного средства | |
| JP2015038135A5 (hr) | ||
| HRP20221269T1 (hr) | Pripravci za liječenje mijelofibroze | |
| JP2016540021A5 (hr) | ||
| JP2009525343A5 (hr) | ||
| HRP20211862T1 (hr) | Pripravci za i postupci liječenja anemije | |
| JP2007091633A (ja) | メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物 | |
| JP2006504795A5 (hr) | ||
| JP2015523407A5 (hr) | ||
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| SI3079671T1 (en) | Oral disintegration solid dosage form containing an esterol component | |
| RU2014115287A (ru) | Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения | |
| WO2015199356A1 (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof | |
| RU2009102443A (ru) | Фармацевтический препарат для контрацепции и для предотвращения риска врожденных пороков развития | |
| HRP20231670T1 (hr) | Farmaceutski pripravak za oralnu primjenu koji sadrži derivat aminopirimidina ili njegovu sol | |
| JP2015537009A5 (hr) | ||
| HRP20200691T1 (hr) | Pedijatrijska formulacija | |
| RU2016106336A (ru) | Противотуберкулезная композиция, содержащая рифампицин, изониазид, этамбутол и пиразинамид, и способ ее получения | |
| RU2019105711A (ru) | Фармацевтическая композиция, содержащая помалидомид |